Solidarity Trial, coordinated by WHO and executed by ICMR in India

The trial tested four repurposed drugs: Remdesivir, Interferon β1a, Lopinavir/Ritonavir and Hydroxychloroquine. Interim analysis showed that no benefits of Remdesivir in any groups of COVID-19 (asymptomatic /mild / moderate /severe /critical) patients. ICMR has succeeded in conducting this large randomized controlled study even during a pandemic situation and earlier lockdown. This study reliably answers to critical public health questions concerning therapeutics. Earlier, ICMR conducted PLACID trial for convalescent plasma indicating no benefit of it in COVID treatment.

Curofy Discussion attached PDF Gallery

5 Likes

LikeAnswersShare

Then how pts improved after antiviral drugs and plasma therapy

Remdesivir with Methylprednisolone quiet effective I personally experienced it. Symptoms decrease after single dose immediately when combined with MPS.

Nice research output by ICMR

Nice informative post Doctor

Nice information